Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.48 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.48 |
| ▸ | ITGAV | P06756 | 1/20 | 0.48 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6774452 | 1.00 | GNPAT (0.51) | GNPATTACR1FOLH1L3MBTL1HDAC3 | |
| SCHEMBL2779453 | 1.00 | GNPAT (0.51) | GNPATTACR1FOLH1L3MBTL1HDAC3 | |
| SCHEMBL13811865 | 0.85 | L3MBTL1 (0.51) | GNPATTACR1FOLH1L3MBTL1HDAC3 | |
| SCHEMBL4404729 | 0.85 | L3MBTL1 (0.51) | GNPATTACR1FOLH1L3MBTL1HDAC3 | |
| SCHEMBL3770263 | 0.85 | SLC7A5 (0.47) | FOLH1L3MBTL1MMEACECPA1 | |
| SCHEMBL3770259 | 0.85 | SLC7A5 (0.47) | FOLH1L3MBTL1MMEACECPA1 | |
| SCHEMBL3002363 | 0.84 | NOS2 (0.55) | GNPATTACR1FOLH1L3MBTL1HDAC3 | |
| SCHEMBL3002357 | 0.84 | NOS2 (0.55) | GNPATTACR1FOLH1L3MBTL1HDAC3 | |
| SCHEMBL9828630 | 0.84 | TACR1 (0.58) | GNPATTACR1FOLH1L3MBTL1ITGB1 | |
| Afalanine SCHEMBL158612 | 0.82 | CTSS (0.65) | GNPATTACR1L3MBTL1LMNACTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6833382-B2 | By muta-synthesis using a mutated micro-organism to influence the biosynthesis of at least one of the precursors of group B streptogramines; mutant strain employed is preferably derived from the strain S. pristinaespiralis SP92 | AVENTIS PHARMA S.A. (FR) | 2004-12-21 | — | — | US | disclosed |
| US-20020142947-A1 | STREPTOGRAMINS AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS | AVENTIS PHARMA, S.A. | 2002-10-03 | — | — | US | disclosed |
| US-6352839-B1 | PREPARING VIRGINIAMYCINS FROM AN ENGINEERED MICROORGANISMS, HAVING THE ABILITY TO PREVENT BIOSYNTHESIS OF THE PRECURSOR ANTIBIOTIC; THE MICROORGANISM IS CULTURED IN THE PRESENCE OF A SECOND PRECURSOR AND THE STREPTOGRAMIN ANALOG IS RECOVERED | AVENTIS PHARMA S.A. (FR) | 2002-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020142947-A1 | STREPTOGRAMINS AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS | EMG1, FBL, SMS | GNPAT 328/4885TACR1 4703/4885FOLH1 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.